AI Model May Predict Immunotherapy Response in Melanoma
Histology slides, clinical data used to predict immune checkpoint inhibitor response in advanced melanoma.
Skin Cancer
Research Shows Long-Term Benefit for Adjuvant Targeted Therapies in High-Risk Melanoma
More than half of patients with resected stage 3 melanoma with BRAF V600E or V600K mutations receiving a year’s worth of adjuvant dabrafenib and trametinib were still alive 5 years later.
Risk of Melanoma Measured in Mutation Burden of Skin Cells
Mutation count could offer personal screening guidelines.
How Do Melanoma Comorbidities Affect Patient Treatment Preferences?
Comorbidities can have an impact on what you as a medical professional think is the best course of treatment for your patients. Can they also affect a patient’s thinking on treatment? Comorbidities such as cardiovascular disease, hypertension, and depression can contribute to how a patient’s body responds to treatment and its attendant stress. A recent…
Racial Disparities in Melanoma-Specific Survival Persist
If, and to what degree, racial disparity in melanoma-specific survival (MSS) has persisted since 2010 was evaluated.
Melanoma Treatment Regimens
View treatment regimens for melanoma, including guidance on options and dosing for a number of drugs including ipilimumab and dacarbazine.
Immunotherapy for the Treatment of Melanoma and Lung Cancer
Immunotherapy has improved outcomes for patients with cancer, despite several drawbacks. This review provides an overview of how to manage patients undergoing therapy with these drugs.
FDA: Small Risk of Skin Cancer With Hydrochlorothiazide Use
Hydrochlorothiazide is indicated for the management of hypertension either as the sole therapeutic agent, or in combination with other antihypertensives.
Prior History of SCC Could Be a Red Flag for Development of SCC in the Setting of CLL
In this study, a cohort of patients with newly diagnosed CLL was followed to identify the incidence of SCC skin cancer and its associated risk factors in this population.
Tecentriq Plus Cotellic and Zelboraf Approved for Advanced Melanoma
The approval was based on data from the multicenter, double-blind, placebo-controlled phase 3 IMspire150 study.
-
Loading...
-
Loading...
Next post in Melanoma
